tbuckley/cabot-search huggingface dataset:
MPTH-08. MOLECULAR INVESTIGATION OF BRAIN TUMORS PROGRESSING DURING PREGNANCY
Authors: Saeko Tanaka, Hikaru Sasaki, Kentaro Ohara, Maya Kono, Katsuhiro Mizutani, Yohei Kitamura, Ryuichi Kanai, Takenori Akiyama, Masahiro Toda, Michihiro Kohno, Kazunari Yoshida
Journal: Neuro-Oncology (2016)

Brain tumors often manifest or progress during pregnancy such as meningiomas, gliomas, and pituitary adenomas. Although its mechanism has not been elucidated well, the literature suggests the presumable association of sex hormones and other growth factors with progression during pregnancy. We collected 5 cases of glioma, 3 cases of meningioma, 2 cases of chordoma and 2 cases of vestibular schwannoma that have manifested or progressed during pregnancy. These tumors were studied for chromosomal copy number abnormality (CNA) by comparative genomic hybridization (metaphase CGH) and the expression of sex hormones and various growth factors and their receptors by immunohistochemistry (including androgen receptor (AR), progesterone receptor (PgR), estrogen receptor(ER), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2), vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and c-Myc). As a result, AR, EGFR, VEGFR-1/2 and c-Myc were expressed in gliomas, ER, PgR, EGFR, HER-2 and VEGFR-1/2 in meningiomas, EGFR, VEGFR-1/2 and c-Myc in chordomas, and VEGFR-1 in vestibular schwannomas. The expression of VEGFR-1/2 and c-Myc was predominantly observed in the tumors progressed during the first and second trimesters. Sex hormone receptors were mainly expressed in the tumors that progressed during the third trimester or postpartum. The expression of EGFR and HER-2 was predominantly observed in the tumors progressed postpartum. CNAs of the tumors progressed during pregnancy varied, however, one anaplastic oligoastrocytoma (IDH mut, non-codeleted) progressed from precedent grade II tumor showed amplification of c-Myc locus. In conclusion, progression of brain tumors during pregnancy is associated with various growth factors, and the driving pathway likely varies dependent on cases.
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial
Authors: T.K. Choueiri, S. Halabi, B. Sanford, O. Hahn, M.D. Michaelson, M. Walsh, T. Olencki, J. Picus, E.J. Small, S. Dakhil, D. George, M.J. Morris
Journal: Annals of Oncology (2016)
Germline mutations predisposing to diffuse large B-cell lymphoma
Authors: O C Leeksma, N F de Miranda, H Veelken
Journal: Blood Cancer Journal (2017)

Abstract Genetic studies of diffuse large B-cell lymphomas (DLBCLs) in humans have revealed numerous targets of somatic mutations and an increasing number of potentially relevant germline alterations. The latter often affect genes involved in DNA repair and/or immune function. In general, defects in these genes also predispose to other conditions. Knowledge of these mutations can lead to disease-preventing measures in the patient and relatives thereof. Conceivably, these germline mutations will be taken into account in future therapy of the lymphoma. In other hematological malignancies, mutations originally found as somatic aberrations have also been shown to confer predisposition to these diseases, when occurring in the germline. Further interrogations of the genome in DLBCL patients are therefore expected to reveal additional hereditary predisposition genes. Our review shows that germline mutations have already been described in over one-third of the genes that are somatically mutated in DLBCL. Whether such germline mutations predispose carriers to DLBCL is an open question. Symptoms of the inherited syndromes associated with these genes range from anatomical malformations to intellectual disability, immunodeficiencies and malignancies other than DLBCL. Inherited or de novo alterations in protein-coding and non-coding genes are envisioned to underlie this lymphoma.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Authors: Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae-Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel A. Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian H. Poehlein, Rodolfo F. Perini, Dean F. Bajorin
Journal: New England Journal of Medicine (2017)

Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options.In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy to receive pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype antibody against programmed death 1 [PD-1]) at a dose of 200 mg every 3 weeks or the investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine. The coprimary end points were overall survival and progression-free survival, which were assessed among all patients and among patients who had a tumor PD-1 ligand (PD-L1) combined positive score (the percentage of PD-L1-expressing tumor and infiltrating immune cells relative to the total number of tumor cells) of 10% or more.The median overall survival in the total population was 10.3 months (95% confidence interval [CI], 8.0 to 11.8) in the pembrolizumab group, as compared with 7.4 months (95% CI, 6.1 to 8.3) in the chemotherapy group (hazard ratio for death, 0.73; 95% CI, 0.59 to 0.91; P=0.002). The median overall survival among patients who had a tumor PD-L1 combined positive score of 10% or more was 8.0 months (95% CI, 5.0 to 12.3) in the pembrolizumab group, as compared with 5.2 months (95% CI, 4.0 to 7.4) in the chemotherapy group (hazard ratio, 0.57; 95% CI, 0.37 to 0.88; P=0.005). There was no significant between-group difference in the duration of progression-free survival in the total population (hazard ratio for death or disease progression, 0.98; 95% CI, 0.81 to 1.19; P=0.42) or among patients who had a tumor PD-L1 combined positive score of 10% or more (hazard ratio, 0.89; 95% CI, 0.61 to 1.28; P=0.24). Fewer treatment-related adverse events of any grade were reported in the pembrolizumab group than in the chemotherapy group (60.9% vs. 90.2%); there were also fewer events of grade 3, 4, or 5 severity reported in the pembrolizumab group than in the chemotherapy group (15.0% vs. 49.4%).Pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory advanced urothelial carcinoma. (Funded by Merck; KEYNOTE-045 ClinicalTrials.gov number, NCT02256436 .).
Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop
Authors: Timothy P. Hughes, Carla Maria Boquimpani, Naoto Takahashi, Noam Benyamini, Nelma Cristina D Clementino, Vasily Shuvaev, Sikander Ailawadhi, Jeffrey H. Lipton, Anna G Turkina, Elena Beatriz Moiraghi, Franck E. Nicolini, Jolanta Dengler, Tomasz Sacha, Dong-Wook Kim, Rafik Fellague-Chebra, Sandip Acharya, Nancy Krunic, Yu Jin, François-Xavier Mahon
Journal: Blood (2016)
Recurrence pattern and its prognostic impact following definitive chemo-radiotherapy in stage III non-small cell lung cancer
Authors: M. Saigi Morgui, A.J. Rullan Iriarte, M. Bergamino, A. Navarro, M.M. Arnaiz, R. Palmero, M. Plana Serrahima, C. Mesía, S. Padrones, S. Aso, J. Ruffinelli Rodriguez, V. Navarro, I. Brao, E. Nadal, F. Cardenal Alemany
Journal: Annals of Oncology (2016)
Bone Morphogenetic Proteins Inhibit CD40L- and IL-21-Induced Ig Production In Human B Cells: Differential Effects of BMP-6 and BMP-7
Authors: Kanutte Huse, Maren Bakkeb∅, Lise Forfang, Vera I. Hilden, Erlend B. Smeland, June H. Myklebust
Journal: Blood (2010)
Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma.
Authors: Natalie M Czuczman, Matthew J. Barth, Richa Dwar, Cory Mavis, Pavel Klener, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2012)
Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up
Authors: Michael Wang, Simon A. Rule, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge Enrique E Romaguera, Jesse McGreivy, Fong Clow, Michelle Stevens-Brogan, Lori Kunkel, Kristie A. Blum
Journal: Blood (2012)
Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes
Authors: Maria Corrales-Yepez, Mohamed A. Kharfan-Dabaja, Jeffrey Lancet, Alan F. List, Eric Padron, Dana Rollison, P.K. Epling-Burnette, Ling Zhang, Teressa Field, Javier Pinilla-Ibarz, Rami S. Komrokji
Journal: Blood (2010)
Complete Cytogenetic Response in a Case of T-PLL with a Complex Karyotype after Treatment with Alemtuzumab.
Authors: André F. Marinato, Fábio Morato de Oliveira, Rafael H. Jácomo, Edgar G. Rizzatti, Roberto P. Falcão, Eduardo M. Rego, Luiz G. Tone, Belinda P. Simões
Journal: Blood (2005)
Allogeneic Halpo-Identical Hematopoietic Stem Cell Transplantation for High-Risk Leukemia
Authors: Jing Bo Wang, Xin Hong Fei, Yu Ming Yin, Hao Yu Cheng, Wei Jie Zhang, Jiang Ying Gu, Song Xue, Qian Li, Fan Yang, Shu Qin Zhang, Jun Bao He, Meng Qi Liu, Jie Zhao, Dai-Hong Liu
Journal: Blood (2015)
EXTH-21. GALLIUM MALTOLATE INTERFERES WITH IRON METABOLISM IN GLIOBLASTOMA
Authors: Mona M. Al-Gizawiy, Janine P. Wereley, Kathleen M. Schmainda, Christopher R. Chitambar
Journal: Neuro-Oncology (2016)

Previously, we presented compelling data that gallium maltolate (GaM) has a profound antitumor effect on glioblastoma (GBM) in vitro and in vivo. We now provide evidence elucidating the mechanism of action by which GaM exerts its antineoplastic activity. Interaction of transferrin with GaM was confirmed by UV-Vis (ultraviolet visible) spectroscopy. Cellular iron proteins and the effects of GaM were evaluated by Western blot and immunohistochemistry (IHC). The action of GaM on the iron-dependent M2 subunit of ribonucleotide reductase (RRM2) was analyzed by Western blot and electron paramagnetic spectroscopy (EPR) in human U87 and D54 GBM cells. Transferrin receptor (TfR) and RRM2 IHC revealed strong expression by GBM tumors, but not by normal brain cells in both patient surgical and U87 xenograft tissues. The keen iron requirement of GBM cells was reflected by the higher proportion of H-ferritin (metabolic) vs. L-ferritin (storage) staining we observed in GBM tumors. More intense TfR staining was noted in treated vs. untreated xenograft tumors. This finding is consistent with an upregulation of TfRs secondary to tumor iron deprivation produced by GaM treatment. Cellularity counts were comparable between GaM-treated and control tumors, but the proportion of dead cells was higher in treated ones. Moreover, the number of mitotic figures was significantly lower in treated tumors (p=0.043). Further analysis of the effect of GaM on RRM2 function showed that GaM formed complexes with transferrin and inhibited the tyrosyl radical of RRM2, and consequently RRM2 activity, without reducing RRM2 protein levels. We propose that GaM exerts its antineoplastic effect by forming identifiable complexes with transferrin, enabling it to be taken up by GBM cells via transferrin receptors, where it interferes with iron-dependent processes, such as DNA synthesis, by inhibition of RRM2 activity. Thus, GaM shows great promise for new interventional strategies in GBM therapy.
Excessive Anti-Viral CD8 T Cell Activation Inverts the IL-2 Consumptive Hierarchy Triggering Regulatory T Cell Collapse in Mouse Model for Hemophagocytic Lymphohistiocytosis
Authors: Stephanie Humblet-Baron, Dean Franckaert, Simon Bornschein, Bénédicte Cauwe, Susann Schonefeldt, Carine Wouters, Patrick Matthys, Frederic Baron, Adrian Liston
Journal: Blood (2015)
EXTH-43. NOVEL LOCAL TREATMENT FOR GLIOBLASTOMA USING SELF-ASSEMBLING HYDROGELS
Authors: Paula Schiapparelli, Montserrat Lara-Velazquez, Ran Lin, Pengcheng Zhang, Hao Su, Hugo Guerrero-Cazares, Honggang Cui, Alfredo Quinones-Hinojosa
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults. Despite surgery and chemo/radiation, recurrence is common. The efficacy of chemotherapy in GBM patients is limited due to the blood brain barrier (BBB). We have developed a self-assembling proprietary camptothecin (SAC) nanofiber hydrogel system for local therapy, with controlled drug release, high penetration into the brain tissue and cytotoxic efficacy in vitro. We evaluated Cy5-labeled SAC in a newly developed animal resection model that replicates the clinical conditions of GBM patients. 20 immunosuppressed mice were injected into the cortex with luciferase-positive primary-cultured human GBM cells. Tumor growth was assessed using bioluminescence (BLI), and tumor resection was performed to recapitulate the human treatment. Mice were randomized into 2 groups (n=10): 1) Resection 2) Resection+SAC. SAC (5µl) was placed in the cavity. Tumor area, drug penetration and survival were determined. Our tumor resection model allowed us to evaluate a new local therapy in a clinically relevant setting. The SAC hydrogel remained in the resection cavity, diffused into the brain parenchyma and decreased tumor growth resulting in prolonged survival. SAC treated animals showed a three-fold decrement in BLI intensity versus non-treated group (p=0.0076). A significantly increased in survival in SAC vs resection only was found (41d vs 35d respectively, p=0.01). Histology revealed a remarkable decreased in tumor growth in the SAC group (p=0.0370, mean=10.47mm2, SEM=1.013mm2). Deep drug brain parenchyma penetration with a mean of 0.7312 ± 0.088 mm2 was found in SAC group. The SAC hydrogel system is an innovative treatment for local cancer therapy that exhibits high penetration and survival benefit. SAC hydrogel is an excellent vehicle for drug delivery in brain cancer, allowing the surgeons have an effect on treatment in the infiltrating part of the tumor, essential for cancer recurrence, disability and death.
In Vitro Functional Rescue of a Double MPL K39N/W272R Mutant Associated with Congenital Amegakaryocytic Thrombocytopenia (CAMT) Using Crispr/Cas9
Authors: Cédric Cleyrat, Romain Girard, Éric Jeziorski, Thierry Lavabre-Bertrand, Sylvie Hermouet, Serge Carillo, Bridget S. Wilson
Journal: Blood (2015)
New insights from KISS activity: a prognostic biomarker in malignant pleural mesothelioma
Authors: V. Ciaramella, C.M. Della Corte, F. Papaccio, V. Giuseppe, G. Esposito, M. Fasano, E. Martinelli, T. Troiani, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2016)
Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment
Authors: Kanstantsin V. Katlinski, Jun Gui, Yuliya V. Katlinskaya, Angelíca Ortiz, Riddhita Chakraborty, Sabyasachi Bhattacharya, Christopher J. Carbone, Daniel P. Beiting, Melanie A. Girondo, Amy R. Peck, Ellen Puré, Priya Chatterji, Anil K. Rustgi, J. Alan Diehl, Constantinos Koumenis, Hallgeir Rui, Serge Y. Fuchs
Journal: Cancer Cell (2017)
Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)
Authors: I. Romero, M.J. Rubio, R. Serrano, M. Medina, L. Minig, A. Casado, P. Coronado, S. Martínez, C. Orbegoso, P. Fusté, E.M. Guerra Alia, M.C. Sánchez-Martínez, D. Rubio, M. Santacana, M. Ruiz, A. Llombart-Cussac, X. Matias-Guiu, A.M. Poveda
Journal: Annals of Oncology (2016)
Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3
Authors: Josh Bornhorst, Adam Rosenthal, Rachael Sexton, Alan Mitchell, Linda Traylor, Antje Hoering, Frits van Rhee, John Crowley, Nathan M Petty, Stephen Harding, Bart Barlogie, Saad Z Usmani
Journal: Blood (2012)
Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party
Authors: Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, Bruno Martino, Giuseppe Rossi, Fabio Stagno, Diamante Turri, Mario Tiribelli, Elena Trabacchi, Alessandro Isidori, Ivana Pierri, Giovanna Leonardi, Patrizia Pregno, Angelo Michele Carella, Maria Teresa Bochicchio, Nicoletta Testoni, Simona Soverini, Giorgina Specchia, Giuliana Alimena, Michele Cavo, Giovanni Martinelli, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Gianantonio Rosti
Journal: Blood (2014)
Low Incidence of CMV Reactivation and Infection after Allogeneic Bone Marrow Transplantation (BMT) Incorporating Post-Transplantation Cyclophosphamide (Cy).
Authors: Heather J. Symons, Leo Luznik, Michele Phelps, Angelita Crawford, Katherine McIntyre, M. Yair Levy, Richard J. Jones, Ephraim J. Fuchs
Journal: Blood (2006)
Spectratype Analysis of In Vitro Donor Anti-Host T Cell Repertoire Responses Predict Those of In Vivo Post-BMT.
Authors: Thea M. Friedman, Kira Goldgirsh, Jenny Zilberberg, Stephanie A. Berger, Joanne Filicko-O’Hara, Neal Flomenberg, Michele Donato, Scott D.D. Rowley, Robert Korngold
Journal: Blood (2007)
Changes in circulating VEGF-A levels related to clinical response during biochemotherapy in metastatic malignant melanoma
Authors: C. Soubrane, R. Mouawad, O. Rixe, J.-P. Spano, M. Gatineau, D. Khayat
Journal: Journal of Clinical Oncology (2004)

7531 Background: high blood levels of vascular endothelial growth factor (VEGF) appear to be associated with a poor prognosis in advanced cancer, probably as a consequence of its angiogenic and immunosuppressive effects. The prognostic significance of serum VEGF levels and its variation during cancer treatment is still unknown. Objectives: The aim of this study is to evaluate the clinical usefulness of active serum vascular endothelial growth factor (sVEGF-A) levels in metastatic malignant melanoma patients and to investigate the possible relationship between sVEGF-A variations and clinical response during biochemotherapy. Patients and Treatment: The study included 73 patients with a fully documented history of metastatic malignant melanoma. Biochemotherapy consisted of Cisplatinum, rIL-2 and Alpha-interferon in two induction cycles. The assessment of clinical response was performed according to WHO criteria. Sixty seven patients were evaluable: 43 % (29/67) were responding (RC&RP) and 57 % were non-responding (13 SD and 25 PD). Methods: active serum VEGF-A concentrations were measured by an enzyme linked immunosorbent assay (ELISA) in the serum of 26 healthy controls and in 75 MMM patients, before and at the end of treatment. Results: pretreatment serum VEGF-A levels in MMM patients were significantly higher than those in controls (p=0.0017). No significant association was noted between sVEGF-A levels and gender, age and LDH level. Serum VEGF-A levels were higher in patients with high tumor burden as compared to patients with low tumor burden. Before treatment, the sVEGF-A level was not significantly different between R and NR patients; at the end of biochemotherapy, an increase of VEGF-A level was correlated to disease progression (r′=0.53,p=0.01) and a decrease of serum VEGF-A levels was correlated to the objective response to treatment (r′=0.43, p=0.02). Conclusion: these results suggest that changes in sVEGF-A levels may represent a useful biomarker to predict the effect of biochemotherapy in terms of clinical response in patients with metastatic malignant melanoma. No significant financial relationships to disclose.
EORTC 21012: Phase II Multicentre Study of Caelyx™ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.
Authors: Reinhard Dummer, Sean Whittaker, Baktiar Hasan, Juergen C Becker, Michael Weichenthal, Rudolf Stadler, Matthias Karrasch, Martine Bagot, Robert Knobler, Maria Bernengo
Journal: Blood (2010)
TMIC-02. TARGETING CARCINOMA–ASTROCYTE GAP JUNCTIONS IN BRAIN METASTASIS
Authors: Adrienne Boire, Qing Chen, Mariza Daras, Thomas Kaley, Krishnaben Patel, Lisa DeAngelis, Joan Massagué
Journal: Neuro-Oncology (2016)

We have recently demonstrated that brain metastatic breast and lung cancer cells assemble carcinoma–astrocyte gap junctions composed of connexin 43 (Cx43) to engage with the astrocyte gap-junctional network. We found that brain metastatic cancer cells use these channels to transfer the second messenger cGAMP to astrocytes, activating the STING pathway and production of inflammatory cytokines such as interferon-α (IFNα) and tumor necrosis factor (TNF). As paracrine signals, these factors activate the STAT1 and NF-κB pathways in brain metastatic cells, thereby supporting tumor growth and chemoresistance. We employed the orally bioavailable modulators of gap junctions meclofenamate and tonabersat to break this paracrine loop to treat established brain metastasis in preclinical mouse models. A pilot study of meclofenamate in patients with recurrent brain metastasis from solid tumor primary cancers is currently underway. This trial, with target accrual of 25 patients, focuses on primary outcomes of feasibility and safety. Thus, this bench-to-bedside strategy has uncovered a key interaction between cancer and the brain parenchyma as well as a novel therapeutic approach to brain metastasis.
NIMG-38. MAPPING OF BRAIN TUMOR OXYGEN METABOLISM IN NATIVE MRI
Authors: Lasse Dührsen, Patrick Borchert, Divya Bolar, Jens Fiehler, Manfred Westphal, Jan Sedlacik, Nils Ole Schmidt
Journal: Neuro-Oncology (2016)

Since hypoxia makes tumors more aggressive and therapy resistant, characterizing blood supply and oxygen consumption may be crucial information for therapy planning and outcome prediction. A new promising method: QUantitative Imaging of eXtraction of oxygen and Tissue consumption (QUIXOTIC) may be able to allow for robust and reliable oxygen consumption mapping. 14 patients, 6 with high grade and 8 with low grade gliomas, were scanned at 3T. The QUIXOTIC method was used to map the oxygen extraction fraction (OEF). After co-registering FLAIR, pCASL and QUIXOTIC images maps of cerebral metabolic rate of oxygen (CMRO2) were calculated. To account for tumor heterogeneity, only voxels with the highest 10% of the measured (high-)OEF/CBF values and their corresponding (corr-)CBF/OEF values were averaged and analyzed, respectively. Parameter maps reveal strong tumor heterogeneity with high variation in OEF, CBF and CMRO2. Higher high-OEF was found for high and low grade gliomas compared to GM control with the corresponding corr-CBF similar for both glioma grades and GM control. High-CBF was lower for high grade gliomas compared to low grade gliomas and GM ­control, whereas corr-OEF was lower for both glioma grades compared to GM control. All parameters were reasonably stable for GM control and showed lower variability as compared to the gliomas. The observed trends of lower corr-CBF with high-OEF and lower corr-OEF with high-CBF are physiologically reasonable, especially for the GM control where a stable and homogeneous CMRO2 is a valid assumption. These findings suggest that the QUIXOTIC method is able to map tumor oxygen metabolism.